ECSP10010211A - Composición - Google Patents

Composición

Info

Publication number
ECSP10010211A
ECSP10010211A EC2010010211A ECSP10010211A ECSP10010211A EC SP10010211 A ECSP10010211 A EC SP10010211A EC 2010010211 A EC2010010211 A EC 2010010211A EC SP10010211 A ECSP10010211 A EC SP10010211A EC SP10010211 A ECSP10010211 A EC SP10010211A
Authority
EC
Ecuador
Prior art keywords
mbp
composition
relates
treat
disease
Prior art date
Application number
EC2010010211A
Other languages
English (en)
Inventor
David Wraith
Heather Streeter
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Publication of ECSP10010211A publication Critical patent/ECSP10010211A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)

Abstract

La presente invención se refiere a una composición que comprende los péptidos de proteína básica de mielina siguientes: MBP 30-44; MBP 83-99; MBP 131-145 y 140-154 MBP. La composición se puede utilizar para tratar una enfermedad, en particular, la esclerosis múltiple y/o neuritis óptica y la invención también se refiere a sus usos y métodos.
EC2010010211A 2007-10-31 2010-05-28 Composición ECSP10010211A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition

Publications (1)

Publication Number Publication Date
ECSP10010211A true ECSP10010211A (es) 2010-08-31

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010211A ECSP10010211A (es) 2007-10-31 2010-05-28 Composición

Country Status (24)

Country Link
US (3) US8623827B2 (es)
EP (1) EP2211892B1 (es)
JP (1) JP5361895B2 (es)
KR (1) KR101570383B1 (es)
CN (1) CN101848725B (es)
AT (1) ATE518546T1 (es)
AU (1) AU2008320657B2 (es)
BR (1) BRPI0818302B1 (es)
CA (1) CA2703170C (es)
CY (1) CY1112620T1 (es)
DK (1) DK2211892T3 (es)
EA (1) EA017999B1 (es)
EC (1) ECSP10010211A (es)
HK (1) HK1142803A1 (es)
HR (1) HRP20110724T1 (es)
IL (1) IL204662A (es)
MX (1) MX2010004698A (es)
MY (1) MY158800A (es)
NZ (1) NZ583924A (es)
PL (1) PL2211892T3 (es)
PT (1) PT2211892E (es)
SI (1) SI2211892T1 (es)
WO (1) WO2009056833A2 (es)
ZA (1) ZA201001748B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230233B1 (hu) 2000-08-21 2015-10-28 Apitope Technology (Bristol) Limited Peptid szelekciós módszer
PT2211892E (pt) 2007-10-31 2011-10-18 Apitope Technology Bristol Ltd Composições compreendendo péptidos de proteína básica de mielina e suas utilizações médicas
ES2566230T3 (es) * 2009-10-12 2016-04-11 Lifebio Laboratories Llc Composición para el tratamiento de la esclerosis múltiple
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
AU2018206356A1 (en) * 2017-01-04 2019-07-18 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Therapeutic method using tolerogenic peptides
CA3072867A1 (en) * 2017-08-14 2019-02-21 Apitope Technology (Bristol) Limited Method
WO2022221622A1 (en) 2021-04-16 2022-10-20 Cour Pharmaceuticals Development Company Inc. Method of tracking maintenance of immunological tolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
HU230233B1 (hu) * 2000-08-21 2015-10-28 Apitope Technology (Bristol) Limited Peptid szelekciós módszer
US20040096456A1 (en) 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
PT2211892E (pt) 2007-10-31 2011-10-18 Apitope Technology Bristol Ltd Composições compreendendo péptidos de proteína básica de mielina e suas utilizações médicas

Also Published As

Publication number Publication date
CY1112620T1 (el) 2016-02-10
US9381234B2 (en) 2016-07-05
EP2211892A2 (en) 2010-08-04
US8623827B2 (en) 2014-01-07
BRPI0818302B1 (pt) 2022-04-12
CN101848725A (zh) 2010-09-29
MX2010004698A (es) 2010-05-13
US9775880B2 (en) 2017-10-03
CA2703170C (en) 2016-10-11
MY158800A (en) 2016-11-15
ATE518546T1 (de) 2011-08-15
HK1142803A1 (en) 2010-12-17
CN101848725B (zh) 2013-05-22
WO2009056833A3 (en) 2009-11-26
CA2703170A1 (en) 2009-05-07
NZ583924A (en) 2012-06-29
KR101570383B1 (ko) 2015-11-19
AU2008320657B2 (en) 2013-09-05
HRP20110724T1 (hr) 2011-12-31
ZA201001748B (en) 2011-06-29
US20160263188A1 (en) 2016-09-15
EP2211892B1 (en) 2011-08-03
EA201070541A1 (ru) 2010-12-30
JP2011500776A (ja) 2011-01-06
WO2009056833A2 (en) 2009-05-07
US20100286054A1 (en) 2010-11-11
PT2211892E (pt) 2011-10-18
IL204662A0 (en) 2010-11-30
KR20100036391A (ko) 2010-04-07
SI2211892T1 (sl) 2011-12-30
PL2211892T3 (pl) 2012-01-31
AU2008320657A1 (en) 2009-05-07
BRPI0818302A2 (es) 2018-08-21
EA017999B1 (ru) 2013-04-30
US20140161832A1 (en) 2014-06-12
IL204662A (en) 2013-07-31
DK2211892T3 (da) 2011-10-31
JP5361895B2 (ja) 2013-12-04

Similar Documents

Publication Publication Date Title
ECSP10010211A (es) Composición
EA201490644A1 (ru) Терапевтические пептиды
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EA201001322A1 (ru) Вакцины против хламидиоза
CO6351811A2 (es) La proteina de tuberculosis rv2386c, composiciones y usos de la misma
EA201001883A1 (ru) Мутанты fgf21 и их применение
EA201171220A1 (ru) Мутанты fgf21 и их применение
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
UY30776A1 (es) Anticuerpos cd44
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
EA201990619A1 (ru) Fgf21 мутанты и их применение
CL2013003328A1 (es) Polipeptidos biespecíficos contra cd32 y cd16 unidos covalentemente a variantes del dominio de unión a la albumina 3 de la proteína g de estreptococo g148, que poseen una vida sérica aumentada; usos; y composiciones farmaceuticas.
MY167231A (en) Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
BR112013005699A2 (pt) moléculas de ligação a 4-1bb
EA201000717A1 (ru) Молекулы и способы, предназначенные для модуляции компонента системы комплемента
EA201792245A1 (ru) Биоконъюгаты и их применения
EA200800667A1 (ru) Аптамеры, связывающие тромбин с высокой аффинностью
CO6400198A2 (es) Composiciones y metodos novedosos
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
NO20071606L (no) Bruk av IL-16 ved vaskulaere komplikasjoner
EA201071163A1 (ru) Применение дефенсинов против менингита
WO2007044989A3 (en) Modulators of nod1 signaling
EA200970792A1 (ru) Аморфный твёрдый раствор, содержащий производное пиразол-3-карбоксамида в аморфной форме и стабилизирующие эксципиенты